CARDLYTICS Reports FY2023 Q2 Earnings, Ending June 30 2023

August 9, 2023

🌥️Earnings Overview

On August 1 2023, CARDLYTICS ($NASDAQ:CDLX) reported its financial results for the second quarter of FY2023, which concluded on June 30 2023. For the period, total revenue was USD 76.7 million, representing a 1.7% year-over-year increase. Net income, however, decreased to -23.5 million from -126.3 million reported in the same quarter of the prior year.

Price History

CARDLYTICS announced its fiscal year 2023 second quarter (Q2) earnings on Tuesday, ending June 30, 2023. The company reported a 3.4% decrease in its stock price, closing at 11.3 from the previous closing price of 11.7 on the same day. As the trading period opened, the stock was priced at 11.6. Profits were also affected by the company’s expansion of its operations into new markets, as well as the launch of new products and services. Analysts have reacted positively to the news of CARDLYTICS’ Q2 earnings.

While market sentiment has been cautious, many believe that the company’s stock has potential for growth and that its current downward trend is likely to be short-term. Overall, CARDLYTICS’ Q2 earnings have been seen as a mixed bag, with both positive and negative aspects to take away from the report. As the company continues to grow and expand, investors hope to see more positive results in the near future. Live Quote…

About the Company

  • CARDLYTICS_Reports_FY2023_Q2_Earnings_Ending_June_30_2023″>Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for Cardlytics. CARDLYTICS_Reports_FY2023_Q2_Earnings_Ending_June_30_2023″>More…

    Total Revenues Net Income Net Margin
    296.24 -381.91 -36.0%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for Cardlytics. CARDLYTICS_Reports_FY2023_Q2_Earnings_Ending_June_30_2023″>More…

    Operations Investing Financing
    -31.85 -12.01 -20.28
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for Cardlytics. CARDLYTICS_Reports_FY2023_Q2_Earnings_Ending_June_30_2023″>More…

    Total Assets Total Liabilities Book Value Per Share
    633.32 397.21 6.96
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for Cardlytics are shown below. CARDLYTICS_Reports_FY2023_Q2_Earnings_Ending_June_30_2023″>More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    14.1% -127.3%
    FCF Margin ROE ROA
    -14.8% -100.6% -37.2%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis

    GoodWhale has conducted an analysis of CARDLYTICS‘s wellbeing and our conclusion is that the company has a low health score of 2/10 according to Star Chart. This puts CARDLYTICS in a vulnerable position, and it is less likely to safely ride out any crisis without the risk of bankruptcy. After taking into account CARDLYTICS’s cashflows and debt, we have classified it as a ‘rhino’, a type of company that has achieved moderate revenue or earnings growth. Looking at CARDLYTICS’s performance more closely, it can be seen that the company is relatively strong in terms of growth but weak in asset, dividend, and profitability. This could be attractive to certain types of investors, such as those looking for high-risk, high-reward investments. However, it is important to note that the weaknesses in CARDLYTICS’s performance could present a significant risk to investors. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Peers

    The company has offices in the United States, United Kingdom, and Germany. Cardlytics Inc’s competitors include Affle India Ltd, Propel Media Inc, and Engage:BDR Ltd.

    – Affle India Ltd ($BSE:542752)

    Affle India Ltd is a technology company that provides consumer insights, engagement, and monetization platforms. The company operates in two segments, Consumer Platform and Enterprise Platform. It offers consumer insights and engagement solutions, such as Appointments, which allows users to schedule appointments with businesses; Deals, which provides users with personalized deals and offers; and Rewards, which allows users to earn rewards for completing tasks. The company also offers an enterprise platform that enables businesses to connect with their customers and employees.

    – Propel Media Inc ($OTCPK:PROM)

    Propel Media Inc is a publicly traded digital media company that operates a number of online properties, including the video sharing website Vimeo. The company was founded in 2004 and is headquartered in New York City. As of 2022, Propel Media had a market capitalization of $19.98 million and a negative return on equity of 67.1%. The company’s primary business is operating Vimeo, which allows users to upload, share, and view videos. The site has over 100 million registered users and generates revenue through advertisements and paid memberships.


    CARDLYTICS reported their earnings results for the second quarter of FY2023 on August 1st, with total revenue of USD 76.7 million and net income of USD -23.5 million, representing a 1.7% increase from the previous year in total revenue and a decrease in net income of -126.3 million. Despite the increase in revenue, investors responded negatively to the news, with the stock price declining on the same day. In light of this news, investors should consider the potential risks associated with investing in CARDLYTICS, as well as its future prospects, before making any decisions.

    Recent Posts

    Leave a Comment